UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers
Source: SeekingAlpha
2026-03-05 01:53:01 ET
...
Read the full article on Seeking Alpha
For further details see:
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers
UroGen Pharma Ltd.
NASDAQ: URGN
URGN Trading
-2.9% G/L:
$19.42 Last:
370,472 Volume:
$20.11 Open:
URGN Latest News
URGN Stock Data
$1,013,880,601
41,940,767
0.31%
40
N/A
Biotechnology & Life Sciences
Healthcare
US
Princeton
